Basilea receives EU market nod for isavuconazole to treat invasive aspergillosis and mucormycosis

2 December 2015

Basilea Pharmaceutica (SIX: BSLN) said the European Commission in October approved the antifungal Isavuconazole (Cresemba) to treat invasive aspergillosis and mucormycosis.

Ronald Scott, Basilea’s chief executive, said: “The European approval of Cresemba for the treatment of invasive aspergillosis and mucormycosis is a key milestone for Basilea. It provides us with the unique opportunity to launch Cresemba as our second hospital anti-infective in Europe and offers an important new therapeutic option to healthcare professionals and their patients suffering from these life-threatening fungal infections.”

Invasive aspergillosis and mucormycosis are life-threatening fungal infections often occurring in patients with cancer and other immunocompromized patients. Isavuconazole will be marketed in Europe under the trade name Cresemba. The drug has European orphan drug status, granting isavuconazole 10 years of market exclusivity in the European Union.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK